Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr

Biopharmaceuticals major Biocon Ltd has reported 17 per cent decline in its net profit to Rs 169 crore during the quarter ended December while the company's topline grew by 7 per cent to Rs 1,879 crore.

ANI | Bengaluru (Karnataka) | Updated: 22-01-2021 10:52 IST | Created: 22-01-2021 10:52 IST
Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr
Growth in research services and biosimilar business segments led to higher revenues.. Image Credit: ANI

Biopharmaceuticals major Biocon Ltd has reported 17 per cent decline in its net profit to Rs 169 crore during the quarter ended December while the company's topline grew by 7 per cent to Rs 1,879 crore. It had posted a net profit of Rs 203 crore and revenues of Rs 1,753 crore in Q3 FY20.

Executive Chairperson Kiran Mazumdar-Shaw said the consolidated revenue for Q3 FY21 was driven by 13 per cent growth in research services and 11 per cent in biosimilar business segments. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter stood at Rs 427 crore with core EBITDA margins at 31 per cent.

"2020 has been one of the most challenging years for the world with an unprecedented pandemic impact on the global economy," said Mazumdar-Shaw. "We continue to face headwinds across operational, regulatory and commercial functions which have been deterrents to our planned market expansion. However, we expect normalisation by next fiscal," she added.

Mazumdar-Shaw said the two recent investments of 225 million dollars in Biocon Biologics by Goldman Sachs and ADQ endorse the value creation of company's biosimilars business. "These investments augur well for our business and will enable us to invest in expanding our research and manufacturing capacities across segments," she said.

The recent launch of Tacrolimus capsules in the United States as well as approvals in Most of the World (MoW) markets for Insulin Aspart, Bevacizumab and Trastuzumab biosimilars will also pave the way for expanding our business in future, added Mazumdar-Shaw. At 10:35 am, Biocon's stock was trading 8.3 per cent lower at Rs 405.25 on BSE Ltd. (ANI)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Addressing conflict-related sexual violence at long last

... ...

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

Raging pandemic shuts down Sao Paulo as Brazil nears Pfizer deal

Brazil set a daily record for COVID-19 deaths for the second straight day on Wednesday, as a raging resurgence of the virus led Sao Paulo state to shutter businesses and the government to try to close vaccine deals with Pfizer and Janssen. ...

PRESS DIGEST- Financial Times - March 4

The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. HeadlinesAmazon opens first physical store outside North America httpson.ft.com309V6pJ German regulator ...

US 'concerned' about dangers of installing networks with equipment that can be manipulated by China

Observing that the Biden administration views 5G as a high priority, the US on Wednesday expressed concern about the dangers of installing networks with equipment that can be manipulated, disrupted, or even controlled by China which it alle...

China reports 10 new COVID-19 cases vs 10 a day earlier

Mainland China reported 10 new COVID-19 cases on March 3, matching the figure from a day earlier, the countrys national health authority said on Thursday. The National Health Commission said in a statement that all of the new cases were imp...

Give Feedback